Related Experiment Video
Updated: Mar 6, 2026

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
Published on: August 11, 2017
Resistance to metronomic chemotherapy and ways to overcome it
Maria Riesco-Martinez1, Karla Parra2, Ronak Saluja3
1Division of Medical Oncology, Hospital Universitario 12 de Octubre, Madrid, Spain.
Abstract:
Therapeutic resistance is amongst the major determinants of cancer mortality. Contrary to initial expectations, antivascular therapies are equally prone to inherent or acquired resistance as other cancer treatment modalities. However, studies into resistance to vascular endothelial growth factor pathway inhibitors revealed distinct mechanisms of resistance compared to conventional cytotoxic therapy. While some of these novel mechanisms of resistance also appear to be functional regarding metronomic chemotherapy, herein we summarize available evidence for mechanisms of resistance specifically described in the context of metronomic chemotherapy. Numerous preclinically identified molecular targets and pathways represent promising avenues to overcome resistance and enhance the benefits achieved with metronomic chemotherapy eventually. However, there are considerable challenges to clinically translate the preclinical findings.
Insights
Therapeutic resistance in cancer is a major challenge. This review summarizes resistance mechanisms specific to metronomic chemotherapy, highlighting preclinical targets for overcoming this resistance.
Area of Science:
- Oncology
- Cancer Therapy
- Drug Resistance
Background:
- Therapeutic resistance significantly contributes to cancer mortality.
- Antivascular therapies, including vascular endothelial growth factor pathway inhibitors, face inherent or acquired resistance.
- Mechanisms of resistance to these therapies differ from conventional cytotoxic treatments.
Purpose of the Study:
- To summarize the specific mechanisms of resistance observed in metronomic chemotherapy.
- To identify promising preclinical molecular targets and pathways for overcoming metronomic chemotherapy resistance.
Main Methods:
- Literature review of studies on resistance to metronomic chemotherapy.
- Analysis of preclinical findings on molecular targets and pathways.
Main Results:
- Novel resistance mechanisms identified for vascular endothelial growth factor pathway inhibitors may also apply to metronomic chemotherapy.
- Several preclinical molecular targets and pathways show potential for enhancing metronomic chemotherapy efficacy.
Conclusions:
- Understanding resistance mechanisms is crucial for improving cancer treatment outcomes.
- Preclinical strategies exist to overcome metronomic chemotherapy resistance, but clinical translation faces challenges.
More Related Videos
08:59Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down
Published on: December 11, 2017
14:51Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype
Published on: June 17, 2022
Related Concept Videos
Treatment Resistant Cancers
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Targeted Cancer Therapies
There are several types of targeted therapies against...
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists
Phenothiazines, such as prochlorperazine...